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Abstract
Introduction: Horner’s syndrome has a variety of etiologies ranging from benign to serious life-threatening
conditions and has been infrequently reported as a presenting symptom of patients with lymphoid neoplasms.
Only one case of Burkitt’s lymphoma presenting with toothache, paresthesia, and Horner’s syndrome has been
described and no case reports of diffuse large B-cell lymphoma as the etiology of Horner’s syndrome currently
exist in the literature. In addition, lymphoid neoplasms have rarely been reported to occur in patients with
neurofibromatosis type 1 despite an increased risk of many types of cancer in such cases.
Case presentation: A 28-year-old Thai man presented with a progressively enlarged left supraclavicular mass
together with a significant weight loss and night sweating for four months. He also noticed hoarseness and ptosis
of his left eye associated with double vision for two months. Physical examination revealed large supraclavicular
lymphadenopathy and Horner’s syndrome (ptosis, miosis, and anhydrosis) on the left side of his face. A large
mediastinal mass was clearly detected by chest X-ray and computed tomography and subsequent lymph node
biopsy provided a diagnosis of diffuse large B-cell lymphoma. Interestingly, the patient was also definitely
diagnosed with neurofibromatosis type 1 from multiple café au lait macules, axillary freckles, three neurofibromas,
multiple Lisch nodules, and a history of affected family members. He subsequently received chemotherapy with a
good response. Twenty-seven cases of various types of lymphoid neoplasms previously reported to occur in
neurofibromatosis type 1 patients were also extracted from the literature. All cases were non-Hodgkin lymphoma
and the major subtype was T-cell. Only nine cases were B-cell lymphoma. The majority of cases were young with a
median age at lymphoma diagnosis of 9.4 years (range 1.1 to 77 years). Two-thirds of the cases were boys or men.
Other concomitant malignancies were brain tumor, colorectal cancer, pheochromocytoma, and acute
lymphoblastic leukemia.
Conclusions: We describe for the first time a case of diffuse large B-cell lymphoma that occurred in a
neurofibromatosis type 1 patient with Horner’s syndrome. Horner’s syndrome can be an initial manifestation of
diffuse large B-cell lymphoma. Patients who present with a classical triad of Horner’s syndrome should always be
fully investigated for lymphomatous involvement, especially in the thorax. The exact molecular mechanism for
diffuse large B-cell lymphoma development in neurofibromatosis type 1 cases remains to be elucidated.
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Neurofibromatosis type 1 (NF1) (formerly known as von
Recklinghausen disease) is an autosomal dominant neu-
rocutaneous disorder characterized by several distinct
clinical features such as café au lait macules, intertrigi-
nous freckling, Lisch nodules, neurofibromas, osseous
dysplasia, and a family history of first-degree relatives
affected by NF1 [1-3]. A variety of neoplasms have been
reported to occur in association with NF1 including
optic pathway gliomas, astrocytomas, brainstem gliomas,
and malignant peripheral nerve sheath tumors
(MPNSTs) [4-6]. Other types of tumors were also
described such as pheochromocytoma, chronic myeloid
leukemia, rhabdomyosarcoma, and gastrointestinal stro-
mal tumors [1,7-9]. However, the existence of lymphoid
neoplasms in patients with NF1, particularly diffuse
large B-cell lymphoma (DLBCL), has been infrequently
reported [1,9].
Horner’s syndrome is a recognized neurological syn-
drome consisting of ptosis, pupillary miosis, and facial
anhydrosis [10]. The syndrome occurs as a result of the
interruption of the oculosympathetic pathway which
could occur along its route from the hypothalamus,
brain stem, spinal cord, brachial plexus, lung apex, caro-
tid artery, cavernous sinus and finally to the eye [10,11].
Three types of Horner’s syndrome exist according to the
anatomical level of the defect, that is, central, pregan-
glionic, and postganglionic [12]. A variety of disorders
have been described in association with Horner’ss y n -
drome ranging from brain stem ischemia, brain tumors,
demyelinating diseases, direct spinal cord trauma, iatro-
genic disruption of the sympathetic pathway from radi-
cal neck dissection, carotid angiography, stenting or
endarterectomy, spontaneous carotid dissection, aortic
aneurysm to various malignant conditions that directly
or indirectly affect the normal sympathetic innervations
[10-12]. Primary and metastatic lung carcinoma, Pan-
coast tumor, thyroid carcinoma, neuroblastoma, Bur-
kitt’s lymphoma, and Hodgkin’sd i s e a s eh a v ea l lb e e n
described as the causes of Horner’s syndrome [10-13].
Interestingly, DLBCL which is the most common hema-
tologic malignancy worldwide has never been shown to
be associated with Horner’s syndrome at the outset. In
addition, the occurrence of DLBCL as the etiology of
Horner’s syndrome in an NF1 patient has not been
described in the literature. We describe for the first
time the case of a young Thai man with NF1 who was
confirmed by pathology as having DLBCL after he pre-
sented with a classical Horner’s syndrome.
Case presentation
A 28-year-old Thai man presented to Siriraj Hospital
with a history of a progressively enlarged left
supraclavicular mass, significant weight loss, and night
sweats for four months.
Two months prior to this admission, he noticed hoar-
seness associated with ptosis of his left eye and double
vision. The physical examination at presentation
revealed ptosis of his left eye with a miotic pupil and
anhydrosis on his left hemifacial area, all of which were
compatible with Horner’s syndrome. His skin examina-
tion disclosed several dermatologic signs such as multi-
ple well-defined brownish café au lait patches on the
abdomen, areolae, arms, back and buttocks, and axillary
freckles (Figure 1). There were also soft movable skin-
colored nodules located on hisl e f tt h i g h ,l e f tf o r e a r m ,
and back. Subsequent ophthalmologic slit-lamp exami-
nation detected multiple Lisch nodules which are raised
pigmented hamartomas of the iris. He reported having
multiple pigmented skin lesions and rubbery nodular
skin lesions over his entire body since childhood. His
father also had similar skin lesions over the whole body
area. Other pertinent examination included a large non-
tender and rubbery mass (15 cm in length and 10 cm in
width) in the left supraclavicular region with no palpable
lymph nodes elsewhere in the body.
Routine laboratory tests revealed a hemoglobin level of
14.5 g⁄dL, a total leukocyte count of 8.2 × 10
9/L (70%
neutrophils, 22% lymphocytes, and 8% monocytes) and a
platelet count of 280 × 10
9/L. Serum lactate dehydro-
genase (LDH) was 525 U/L (normal range, 225 to 450
U/L) and serum uric acid was 13.4 mg/dL (normal
range, 2.4 to 7 mg/dL). His liver function tests were
normal. Chest X-ray revealed a large anterior mediast-
inal mass (Figure 2). Computed tomography (CT) of his
neck showed matted lymphadenopathy on the left side
of the neck, which extended along the carotid vessels to
the left thoracic cavity. Computed tomography (CT) of
the chest disclosed a large (10.9 × 9.7 × 18 cm) lobu-
lated heterogeneous-enhancing mass with a central
necrosis in the anterior and middle mediastinum which
extended superiorly into the left anterior neck (C5-C6
level), and encased around his aortic arch, left subcla-
vian artery, left jugular vein, trachea, left main bronchus
and left pulmonary artery (Figure 3A). Multiple subcen-
timeter mediastinal lymphadenopathies were also
observed. Left pleural effusions with adjacent atelectasis
of the left lower lobe were also present. From these
findings, the differential diagnoses of this mass were
lymphoma, teratoma, lung cancer or metastasis and
malignancy associated with NF1, such as MPNSTs and
chromaffin cells tumor. Therefore, supraclavicular
l y m p hn o d eb i o p s yw a sp e r f o r m e dt om a k ead e f i n i t e
pathological diagnosis which revealed diffuse, mixed
small and large lymphoid cells compatible with malig-
nant lymphoma (intermediate grade). Immunostaining
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marked with CD20, CD10, CD43, BCL2, BCL6, and
MUM1, but not with CD3, CD5, CD23, CD34, TdT, or
cyclin D1. Kappa but not lambda light chain restriction
was also demonstrated. The malignant cells possessed a
B-cell phenotype with mixed germinal center B-cell and
activated B-cell features which were consistent with a
DLBCL subtype according to the 2008 World Health
Organization (WHO) Classification of neoplasms of the
hematopoietic and lymphoid tissues [14]. Staging studies
showed no bone marrow involvement and computed
tomography (CT) of the whole abdomen revealed nor-
mal attenuation of liver parenchyma without a definite
space occupying lesion. The spleen was unremarkable
and no intraabdominal lymphadenopathy could be
demonstrated. Once the diagnosis and the staging were
completed, he was treated with the standard CHOP
(Cyclophosphamide (Cytoxan), Hydroxyrubicin (Adria-
mycin), Oncovin (Vincristine), Prednisone) chemother-
apy regimen for eight cycles, to which the tumor
responded well (Figure 3B).
Discussion
This report describes the case of an NF1 patient who
presented with a rare manifestation of malignant lym-
phoma, that is, Horner’s syndrome. In our case, NF1
could be definitely diagnosed according to the National
Institute of Health Consensus Development Conference
Diagnostic Criteria which require the presence of six or
more café au lait macules, two or more subcutaneous
Figure 1 The patient’s clinical presentations;neck mass (A), axillary freckles (B), café-au-lait macules (C), and neurofibroma (D).
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more Lisch nodules seen on slit lamp examination [2].
An autosomal dominant family history was also demon-
strated in this patient which goes along well with the
typical NF1 inheritance pattern. Although it is well-
known that NF1 patients have an increased risk of
malignancies with an estimated risk of 5% to 15% in
affected individuals, most reported types of malignancies
are not lymphoid neoplasms [8,15]. Since the association
between NF1 and malignant lymphoma is not fully
recognized, we searched the literature through the US
National Library of Medicine (PUBMED) using the
Figure 2 Chest X-ray revealed a large anterior mediastinal mass.
Figure 3 Computed tomography (CT) of the neck and chest showed a large lobulated heterogeneous-enhancing mass with central
necrosis at the anterior and the middle mediastinum with some parts extending into the left anterior neck (A). Significant improvement
of lymphomatous involvement at the prevascular region was seen after eight cycles of CHOP chemotherapy (B). CHOP, Cyclophosphamide
(Cytoxan), Hydroxyrubicin (Adriamycin), Oncovin (Vincristine), Prednisone.
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“neurofibromatosis” to find out if malignant lymphoma
had been previously reported in NF1 cases and how fre-
quently they had appeared in the literature. Only 27
cases of malignant lymphoma were reported in NF1
patients [7,16-34], and only two of them were DLBCL
[27,33]. Table 1 summarizes details of all the reported
cases except one case that was published in the non-
English literature [35].
With respect to the symptoms of NF1 in the
reported series, 20 cases had café au lait macules
(CALM), 13 cases had neurofibromas, five cases had
axillary or inguinal freckles, and three cases had Lisch
nodules. These cases were typical of NF1 in which
CALM, neurofibroma and skin-fold freckling are the
main symptoms [36]. Most of the reported cases (17
cases) had a family history of neurofibromatosis.
Twelve cases had family members with neurofibroma-
tosis and malignancies. All cases were diagnosed with
non-Hodgkin’s lymphoma (NHL). The majority of
cases were young with a mean age of 23 years (range
1.1 to 77 years; median 9.4 years) at lymphoma diag-
nosis and two-thirds of the cases were boys and men.
The lymphoma subtype was predominantly T-cell (13
of 25 cases), especially T-lymphoblastic lymphoma
(five cases) and cutaneous T cell lymphoma (two
cases). Nine cases had B-cell lymphoma and five cases
had unclassified lymphoma. Six cases presented with a
mediastinal mass and others presented with a head
and neck mass (three cases), an abdominal mass (three
cases), lymphadenopathy (two cases), skin rash (two
cases), a localized brain lesion (one case), and a
shoulder mass (one case). No NF1 patients in prior
series were reported to present with Horner’ss y n -
drome. Other concomitant malignancies identified
were brain tumors (four cases), colorectal cancer (two
cases), pheochromocytoma (two cases), and acute lym-
phoblastic leukemia (ALL) (two cases). One case devel-
oped ALL prior to NHL [21] and the remaining case
developed ALL 15 months after diagnosis of NHL [7].
Additional disorders found among the 26 cases were
Gardner syndrome (one case) and Gaucher’s disease
(one case). Thirteen cases received standard che-
motherapy while six cases received radiotherapy. None
of the NF1 cases received stem cell transplantation.
Ten patients (37%) responded to therapy and survived.
Our patient also responded well to eight cycles of
CHOP chemotherapy with resolution of his Horner’s
syndrome and disappearance of all tumor masses.
Immunotherapy such as rituximab was not given in
this particular patient due to limited availability of
health insurance coverage for such costly drugs in the
country.
Although the central nervous system involvement of
malignant lymphoma is well documented, the inter-
ruption of the sympathetic pathway causing Horner’s
syndrome is an unusual manifestation of malignant
lymphoma [37]. In our current review of the literature,
there was only one described case of Burkitt’sl y m -
phoma presenting with toothache, paresthesia and
Horner’s syndrome [13,37]. Hodgkin’s disease was also
infrequently reported [7,16-34]. No cases of DLBCL as
the cause of Horner’s syndrome have been described
in the literature. The mechanism of Horner’ss y n -
drome in this patient could be explained by the
aggressive nature of DLBCL creating a huge mass in
the anterior and middle mediastinum which encased
his aortic arch, subclavian artery, left jugular vein, and
left pulmonary artery, and extended to his left neck
along the carotid vessels. The tumor mass could
potentially affect the oculosympathetic pathway that
normally enters the thorax, crosses the lung apex, and
subsequently runs along the carotid vessels to the
eyes.
The direct association between NF1 and T-cell lym-
phoma in most previously reported cases or between
NF1 and DLBCL in this present case is unclear. The
NF1 gene is a tumor suppressor gene and multiple key
pathways are potentially involved in the development of
cancer in NF1 cases such as RAS/mitogen-activated pro-
tein kinase (MAPK) and AKT/mammalian target of
rapamycin (mTOR) [38,39]. Germline mutations of the
NF1 generally result in decreased intracellular neurofi-
bromin protein levels and lead to increased RAS signal-
ing to its downstream effectors [38]. Mutations in the
DNA mismatch repair genes, such as MLH1 (human
mutL homolog 1) [24,25] and MSH6 (human mutS
homolog 6), have been reported in NF1 cases with
malignant lymphoma (as shown in Table 1), early-onset
CNS tumors, and colorectal cancer [31]. Lymphoma
potentially occurs in NF1 patients through a series of
proto-oncogene activation and mismatch repair gene
mutations although the precise pathogenetic mechanism
needs to be further explored.
Conclusion
DLBCL has never been shown to manifest initially as
Horner’s syndrome. To the best of our knowledge, our
case represents the first case ever of Horner’s syndrome
that occurred as a result of oculosympathetic interrup-
tion by DLBCL. This case reveals a rare association
between NF1 and DLBCL in contrast to other more
common non-hematologic malignancies that frequently
occurred in NF1 cases. Molecular mechanisms required
for the initiation and propagation of lymphoma in NF1
cases should be determined to answer why and how
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Case
No.
References Sex/
Age at
onset
(y)
Lymphoma Other tumor(s) Presentation of
lymphoma
Family
history
of
NF1
Family
history
of
cancer
NF criteria* Treatment Outcome
1. [16] F, 20 Burkitt lymphoma Pheochromocytoma dental extract site
mass
NA NA CALM, neurofibromas Chemotherapy
and
radiotherapy
Alive
2. [17] M, 11 Diffuse, poorly
differentiated
lymphoma
Glioblastoma multiforme anterior mediastinal
mass
Y Y CALM Chemotherapy Death
3. [18] F, 6 T-cell lymphoblastic
lymphoma
Gardner syndrome mediastinal mass
and pleural effusion
Y Y CALM Chemotherapy
and
radiotherapy
Death
4. [18] F, 1.1 T-cell lymphoblastic
lymphoma
neck mass Y Y CALM Radiotherapy Death
5. [18] M, 4 T-cell lymphoblastic
lymphoma
mediastinal mass
and pleural effusion
Y Y CALM, neurofibromas Chemotherapy
and
radiotherapy
Death
6. [7] M, 16 T-cell lymphoma Acute lymphoblastic leukemia,15
months after diagnosis of
lymphoma
mediastinal mass Y Y CALM Chemotherapy
and
radiotherapy
Death
7. [19] M, 45 Well-differentiated
lymphocytic lymphoma
Pheochromocytoma, renal artery
stenosis
abdominal mass NA NA CALM, neurofibromas NA Alive
8. [20] M, 59 Diffuse, medium sized
cell type, B cell type
NHL
lymphadenopathy Y NA CALM, neurofibromas Chemotherapy Death
9. [21] M, 7.8 T-NHL Acute lymphoblastic leukemia,
prior to NHL
Y Y NA NA Death
10. [21] F, 4.1 T-NHL Y Y NA NA Death
11. [21] M, 1.6 T-NHL Y Y NA NA Death
12. [21] M, 13.7 Mixed
centroblastic/
centrocytic NHL
Y NA NA NA Alive
13. [21] M, 7.2 B- NHL N NA NA NA Death
14. [22] F, 4.6 B-cell NHL Glioblastoma multiforme right iliac fossa mass N N CALM, neurofibromas Chemotherapy Alive
15. [23] M, 65 Diffuse mixed type, T
cell type NHL
generalized
lymphadenopathy
Y NA CALM, neurofibromas Chemotherapy Death
16. [24] F, 2** Undifferentiated NHL Y Y CALM, neurofibromas,
pseudoarthrosis
NA Death
17. [25] M, 3.3** NHL Y Y CALM NA Death
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9Table 1 Summarized data of all reported NF1 cases with lymphoma development (Continued)
18. [26] M, 44 Cutaneous T-cell
lymphoma
Astrocytoma skin rash NA NA CALM, neurofibromas,
freckles
Phototherapy
and topical
steroid
Alive
19. [27] F, 77 DLBCL left lower abdominal
mass and weight
loss
Y NA CALM, neurofibromas Chemotherapy Alive
20. [28] M, 2 T-cell NHL Colorectal cancer testicular and
mediastinal mass
Y NA CALM, freckle Chemotherapy
and
radiotherapy
Alive
21. [29] M, 72 Cutaneous T-cell
lymphoma
skin rash Y NA CALM, neurofibromas,
freckles, Lisch
nodules
NA Alive
22. [30] M, 47 CNS lymphoma, B cell
type
parieto-occipital lobe
mass
NA NA Neurofibromas, Lisch
nodules
NA NA
23. [31] M, 9.4 T-cell lymphoma Anaplastic astrocytoma mediastinal mass N Y CALM, freckles Chemotherapy Death
24. [32] M, 5*** Lymphoblastic
lymphoma
Colorectal cancer Y Y CALM, freckles NA Death
25. [33] F,50 DLBCL shoulder mass N N CALM, neurofibromas Chemotherapy Alive
26. [34] F, 6 Mediastinal T-cell
lymphoblastic
lymphoma
Gaucher’s disease NA NA NA NA NA
27. Present
case
M, 28 DLBCL neck mass N N CALM, neurofibromas,
freckles, Lisch
nodules
Chemotherapy Alive
Abbreviations: CALM, café au lait macules; CNS, central nervous system; DLBCL, diffuse large B-cell lymphoma; F, female; M, male; N, No; NA, not available; NF, neurofibromatosis; NF1, neurofibromatosis type 1; NHL,
non-Hodgkin’s lymphoma; y, years; Y, Yes;
*Freckles include axillary or inguinal freckles
** Presence of MLH1 (human mutL homolog 1) mutation
***Presence of MSH6 (human mutS homolog 6) mutation
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9only a very few NF1 cases are at risk of lymphoma
development in their lifetimes.
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